

Antengene collaborates with WuXi Biologics, WuXi STA for ADC asset

03 February 2021 | News

Through this collaboration, WuXi Biologics and WuXi STA will provide services for the process development, scale-up, and GMP manufacturing of ADC drug intermediates



Antengene Corporation Limited, a China based innovative biopharmaceutical company dedicated to discovering, developing and commercialising global first-in-class and/or best-in-class therapeutics in haematology and oncology, has announced that it has entered into a strategic collaboration with WuXi Biologics, and STA Pharmaceutical Co, Ltd (WuXi STA), a leading contract development and manufacturing organisation to accelerate the discovery, development and manufacturing of the company's antibody-drug conjugate (ADC) asset.

Through this collaboration, WuXi Biologics and WuXi STA will provide services for the process development, scale-up, and GMP manufacturing of ADC drug intermediates. Antengene will focus on the discovery of the monoclonal antibody, the core element of ADCs.

WuXi STA will focus on the GMP manufacturing of linkers and payloads while WuXi Biologics will provide process development for monoclonal antibody and the biological conjugation as well as the subsequent GMP manufacture.

Dr Jay Mei, Founder, Chairman and CEO, Antengene, commented, "We are pleased to form such synergistic and long-term partnerships with WuXi STA and WuXi Biologics. Through strategic alliances and further integrating our clinical development, regulatory, and early discovery teams, we are rapidly advancing our in-house discovery programmes. I am confident that together we can bring our ADC asset towards clinical development with clinical applications that will ultimately bring benefit to patients in need."

Dr Bo Shan, Corporate Vice President of Discovery, Early Development and CMC, Antengene, said, "We believe this collaboration will enable Antengene to utilise an advanced manufacturing process and quality management system for the discovery and manufacturing of high-quality ADCs for use in clinical development, and thereby further strengthen Antengene's core competitiveness in global drug development landscape."

